David Ricks, Eli Lilly CEO (Al Drago/Bloomberg via Getty Images)

Lil­ly to build man­u­fac­tur­ing ca­pac­i­ty at risk to pre­pare for next-gen oral obe­si­ty drug

Eli Lil­ly is stuck in a hard place — it’s got the cap­i­tal to spend to boost man­u­fac­tur­ing ca­pac­i­ty. But the com­plex­i­ty of build­ing, buy­ing and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.